Apixaban Drug Interactions and Management

Critical Drug Interactions

The American College of Cardiology recommends reducing the apixaban dose by 50% when combined with strong dual P-gp and CYP3A4 inhibitors, such as ketoconazole, itraconazole, ritonavir, and clarithromycin, in patients taking apixaban 5 mg or 10 mg twice daily 1
The American College of Cardiology advises avoiding coadministration of apixaban with strong dual P-gp and CYP3A4 inhibitors entirely in patients already taking apixaban 2.5 mg twice daily 1
A retrospective study demonstrated that clarithromycin, a strong dual inhibitor, was associated with higher rates of hospitalization for major bleeding compared to azithromycin, a P-gp inhibitor only, in patients taking DOACs 2

The American College of Cardiology and European Heart Journal recommend avoiding apixaban use with strong inducers, such as rifampin, carbamazepine, phenytoin, and St. John's wort, as these markedly reduce apixaban plasma levels and increase thrombotic risk 1, 3, 4
Pharmacokinetic studies show rifampin significantly decreases apixaban area under the curve (AUC), potentially leading to treatment failure 2

The European Heart Journal notes that diltiazem causes a 40% increase in apixaban plasma concentrations but generally does not require dose adjustment unless combined with other risk factors, such as age ≥80 years, weight ≤60 kg, creatinine ≥1.5 mg/dL, or multiple bleeding risk factors 3, 5
Verapamil has variable effects on apixaban depending on formulation, but specific interaction data are limited; exercise caution when combining 3, 5

The American College of Cardiology recommends dose reduction to 2.5 mg twice daily if patients meet at least 2 of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL 1
Unlike dabigatran, apixaban has only 27% renal clearance, making it less sensitive to renal impairment 1

The American College of Cardiology recommends limiting concomitant use of antiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, with apixaban to situations where dual or triple therapy is absolutely necessary, as it increases bleeding risk 6

The American College of Cardiology recommends discontinuing apixaban at least 48 hours before elective surgery or procedures with moderate-to-high bleeding risk, and at least 24 hours before low-bleeding-risk procedures 7

The American College of Cardiology recommends andexanet alfa as the FDA-approved specific reversal agent for apixaban-associated life-threatening bleeding, with a low-dose regimen of 400 mg IV bolus at 30 mg/min followed by 4 mg/min infusion for up to 120 minutes, or a high-dose regimen of 800 mg IV bolus at 30 mg/min followed by 8 mg/min infusion for up to 120 minutes 6
If andexanet alfa is unavailable, four-factor prothrombin complex concentrate (4F-PCC) or activated PCC may be considered, though not specifically studied for apixaban reversal 6

Carbamazepine is a potent inducer of both P‑glycoprotein (P‑gp) and CYP3A4 enzymes, the primary pathways responsible for apixaban metabolism and elimination. This dual induction markedly lowers apixaban plasma concentrations, risking therapeutic failure. 8

The 2023 ACC/AHA/ACCP/HRS guidelines explicitly advise avoiding apixaban when co‑administered with strong P‑gp/CYP3A4 inducers such as carbamazepine, phenytoin, rifampin, and St. John’s wort. This recommendation is issued irrespective of renal function or other patient characteristics. 8
The 2014 AHA/ACC/HRS guidelines similarly state that co‑administration of apixaban with P‑gp inducers, including carbamazepine, should be avoided. [9][10]

Switching to warfarin with INR monitoring (target 2.0–3.0) is recommended because warfarin metabolism is less affected by carbamazepine and dosing can be adjusted based on INR values. Frequent INR checks (e.g., weekly initially, then every 2–4 weeks) are advised when carbamazepine is started or stopped. [8][9]
Warfarin is considered the safest oral anticoagulant option when a strong enzyme inducer such as carbamazepine is required for seizure or mood‑disorder management. [8][9]

Other enzyme‑inducing antiepileptics (e.g., phenytoin, phenobarbital, primidone) must not be used as substitutes because they produce the same P‑gp/CYP3A4 induction and reduce apixaban exposure. 8
Switching to other direct oral anticoagulants such as rivaroxaban or dabigatran is contraindicated, as they are also P‑gp substrates and exhibit similar reductions in plasma levels when combined with carbamazepine. 8